Mission 

Our goal of this Co-Clinical Imaging Research Program (CIRP) (Project Number: 1U24CA253377) is to overcome the translational barrier, to develop co-clinical imaging research resources that will encourage a consensus on how quantitative imaging methods are optimized to improve the quality of imaging results for co-clinical trials. This will be accomplished by using novel quantitative metabolic preclinical hyperpolarized (HP) ¹³C magnetic resonance imaging (MRI) to assess therapeutic response of small cell neuroendocrine (SCNC) prostate cancer (PCa). Although this proposal will focus on current standard of care treatment, the new quantitative HP ¹³C metabolic MRI approaches developed in this proposal will have general applicability for a variety of new targeted therapeutic approaches being developed for SCNC as well as for the study of other diseases.
 

Website Resources 

This Co-Clinical Imaging Research Program website is a portal for quantitative HP ¹³C MRI protocols, data analyses tools, and correlative biology data which will provide a better understanding on how quantitative HP ¹³C MRI can be used in co-clinical imaging trials to improve the assessment of therapeutic response and resistance. While this project focuses on advanced prostate cancer, these new quantitative metabolic imaging techniques could ultimately benefit the clinical management of other cancers and diseases.